UK Markets close in 8 hrs 21 mins

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8900+0.2700 (+10.31%)
At close: 04:00PM EDT

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees215

Key executives

NameTitlePayExercisedYear born
Dr. Mondher Mahjoubi M.D.Chairman of Exec. Board & CEO1.09MN/A1958
Mr. Yannis Morel Ph.D.Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board431.6kN/A1973
Dr. Herve BraillyCo-Founder & Chairman of Supervisory BoardN/AN/A1961
Dr. François RomagnéFounderN/AN/A1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.Founder, Sr. VP & Chief Scientific OfficerN/AN/A1964
Dr. Marc Bonneville Ph.D.FounderN/AN/A1960
Mr. Jean Jacques Fournié Ph.D.FounderN/AN/AN/A
Mr. Alessandro Moretta M.D., Ph.D.FounderN/AN/AN/A
Mr. Frederic Lombard M.B.A.Sr. VP & CFON/AN/A1975
Ms. Odile BelzunceVP of Compliance & OperationsN/AN/A1980
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Corporate governance

Innate Pharma S.A.’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.